

Scan W/RCE 09/03/09
**IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE**

Serial No. : 10/525,986
Applicants : Tadashi NAKAJIMA et al.
Filed : February 25, 2005
For : THERAPEUTIC AGENT FOR
GLAUCOMA COMPRISING Rho
KINASE INHIBITOR AND
PROSTAGLANDIN
Art Unit : 1612
Examiner : Sean M. BASQUILL
Docket No. : 05116/HG
Confirm. No.: 5004
Customer No.: 01933

EXPEDITED PROCEDURE
REPLY UNDER 37 CFR 1.116
TECHNOLOGY CENTER 1600

This paper is being submitted
via EFS-Web on

July 10, 2009

In the event that this Paper
is late filed, and the
necessary petition for
extension of time is
not filed concurrently
herewith, please consider
this as a Petition for the
requisite extension of time,
and to the extent not already
paid, authorization to charge
the extension fee to Account
No. 06-1378. In addition,
authorization is hereby given
to charge any fees for which
payment has not been submitted,
or to credit any overpayments,
to Account No. 06-1378.

AMENDMENT UNDER 37 CFR 1.116

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

MAIL STOP AF

S I R :

This is in response to the Office Action mailed January 12,
2009, the term for response to which is extended three months by
a PETITION FOR EXTENSION OF TIME filed concomitantly herewith to
expire on July 12, 2009. A Notice of Appeal is being filed
concomitantly herewith. Please amend the above-identified
application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which
begins on page 5 of this paper.

Remarks begin on page 8 of this paper.